Thiazide prophylaxis of urolithiasis. A double-blind study in general practice.
Thiazide prophylaxis of urolithiasis. A double-blind study in general practice.
复制标题
噻嗪类药物预防尿石症。
DOI：
10.1007/978-1-4684-7272-1_101
复制
发表时间：
2009
影响因子：
--
通讯作者：
Stig Larsen
中科院分区：
文献类型：
--
作者：
E. Lærum;Stig Larsen
挪威全科诊所进行的一项双盲随机研究（中位时间为 3 年）纳入了 50 名复发性结石患者，以比较每天两次服用 25 毫克氢氯噻嗪与安慰剂的情况。安慰剂组中出现新结石的患者数量显着高于噻嗪组（p=0.05，单尾检验）。如果形成新结石，噻嗪类药物（而非安慰剂）具有延长无结石时间间隔的作用（p≤0.01）。安慰剂组在治疗期间不形成新结石的概率为 45%，噻嗪组为 75%。噻嗪类药物的作用似乎与尿钙无关，但对高尿酸尿患者的益处较小。安慰剂组的新结石预期数量也显着减少（p≤0.01），强调了适当对照组的重要性。
Fifty recurrent stone formers were included in a double‐blind randomized study (median 3 years) performed in a Norwegian general practice to compare twice daily administration of 25 mg hydrochlorothiazide versus placebo. The number of patients with new stones was significantly higher in the placebo group than in the thiazide group (p=0.05, one‐tailed test). If a new stone was formed, thiazide, but not placebo, had the effect of prolonging the stone‐free interval (p≤0.01). The probability of not forming a new stone during the treatment period was 45% for the placebo group and 75% for the thiazide group. The thiazide effect seemed to be independent of urinary calcium, but was less beneficial in patients with hyperuricosuria. The placebo group also showed a substantial decrease in the expected number of new stones (p≤0.01), emphasizing the importance of an adequate control group.